Two DHH Subfamily 1 Proteins Contribute to Pneumococcal Virulence and Confer Protection against Pneumococcal Disease

Infection and Immunity - Tập 79 Số 9 - Trang 3697-3710 - 2011
L. E. Cron1, Kim Stol1, Peter Burghout1, Saskia van Selm1, Elles Simonetti1, Hester J. Bootsma1, Peter W. M. Hermans1
1Laboratory of Pediatric Infectious Diseases, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

Tóm tắt

ABSTRACT Streptococcus pneumoniae is an important human bacterial pathogen, causing such infections as pneumonia, meningitis, septicemia, and otitis media. Current capsular polysaccharide-based conjugate vaccines protect against a fraction of the over 90 serotypes known, whereas vaccines based on conserved pneumococcal proteins are considered promising broad-range alternatives. The pneumococcal genome encodes two conserved proteins of an as yet unknown function, SP1298 and SP2205, classified as DHH (Asp-His-His) subfamily 1 proteins. Here we examined their contribution to pneumococcal pathogenesis using single and double knockout mutants in three different strains: D39, TIGR4, and BHN100. Mutants lacking both SP1298 and SP2205 were severely impaired in adherence to human epithelial Detroit 562 cells. Importantly, the attenuated phenotypes were restored upon genetic complementation of the deleted genes. Single and mixed mouse models of colonization, otitis media, pneumonia, and bacteremia showed that bacterial loads in the nasopharynx, middle ears, lungs, and blood of mice infected with the mutants were significantly reduced from those of wild-type-infected mice, with an apparent additive effect upon deletion of both genes. Minor strain-specific phenotypes were observed, i.e., deletion of SP1298 affected host-cell adherence in BHN100 only, and deletion of SP2205 significantly attenuated virulence in lungs and blood in D39 and BHN100 but not TIGR4. Finally, subcutaneous vaccination with a combination of both DHH subfamily 1 proteins conferred protection to nasopharynx, lungs, and blood of mice infected with TIGR4. We conclude that SP1298 and SP2205 play a significant role at several stages of pneumococcal infection, and importantly, these proteins are potential candidates for a multicomponent protein vaccine.

Từ khóa


Tài liệu tham khảo

10.1128/iai.62.12.5683-5688.1994

10.1016/S0968-0004(97)01162-6

10.1073/pnas.0511017103

10.1128/iai.63.2.448-455.1995

10.1046/j.1365-2958.2001.02448.x

10.1128/IAI.72.4.2416-2419.2004

10.1046/j.1365-2958.2003.03557.x

10.1128/AEM.01900-06

10.1128/IAI.71.8.4405-4413.2003

10.1016/S1473-3099(04)00938-7

10.1128/IAI.01823-06

10.1128/JCM.00140-07

10.1128/IAI.00031-07

10.1128/IAI.68.2.796-800.2000

10.1086/376571

10.1046/j.1365-2958.2001.02414.x

10.1371/journal.ppat.0030168

10.1128/JB.00573-07

10.1099/mic.0.026765-0

10.1016/S1535-6108(04)00021-2

DaveS.PangburnM. K.PruittC.McDanielL. S.. 2004. Interaction of human factor H with PspC of Streptococcus pneumoniae. Indian J. Med. Res. 119(Suppl.):66–73.

10.1046/j.1365-2958.1997.5111879.x

10.1128/iai.12.4.772-778.1975

10.1128/iai.18.2.291-297.1977

10.1099/mic.0.28433-0

10.1016/S0022-2836(83)80284-8

HavaD. L.CamilliA.. 2002. Large-scale identification of serotype 4 Streptococcus pneumoniae virulence factors. Mol. Microbiol. 45:1389–1406.

10.1128/JB.00917-07

10.1128/JB.01144-06

HermansP. W. M.. October 2008. New virulence factors of Streptococcus pneumoniae. Netherlands patent PCT/NL2008/050191.

HermansP. W. M.. October 2009. New virulence factors of Streptococcus pneumoniae. Netherlands patent PCT/NL2009/050600.

10.1016/0378-1119(89)90051-6

10.4049/jimmunol.168.4.1886

10.1128/IAI.72.7.3902-3906.2004

10.1128/IAI.00543-06

10.1111/j.1365-2958.1996.tb02613.x

10.1046/j.1365-2958.2001.02335.x

10.1186/1471-2334-9-121

10.1006/meth.2001.1262

10.1016/0882-4010(92)90116-6

10.1016/0882-4010(88)90007-1

10.1073/pnas.86.8.2627

10.1128/IAI.70.3.1422-1433.2002

10.1111/j.1365-2958.2003.03917.x

10.1128/iai.59.1.222-228.1991

10.1093/nar/gkm462

10.1128/IAI.00631-10

10.1128/IAI.67.9.4517-4524.1999

10.1128/IAI.68.5.3028-3033.2000

10.1128/IAI.01103-06

10.1128/IAI.01384-06

10.1128/IAI.69.10.5997-6003.2001

10.1128/IAI.72.10.5582-5596.2004

10.1084/jem.176.2.415

10.1146/annurev.mi.47.100193.000513

10.1128/iai.43.3.1085-1087.1984

10.1128/IAI.66.12.5620-5629.1998

10.1074/jbc.M109.040238

10.1128/IAI.72.1.114-122.2004

10.1128/IAI.71.1.75-85.2003

10.1086/432513

10.1099/mic.0.033175-0

10.1128/JB.181.19.6098-6102.1999

10.1099/0022-1317-51-5-361

10.1126/science.1061217

10.1016/j.cell.2005.02.033

10.1016/S0264-410X(03)00501-2

10.1128/IAI.67.9.4720-4724.1999

10.1016/j.vaccine.2010.02.086

10.1128/IAI.69.3.1593-1598.2001

10.1086/513980

10.1128/IAI.00473-09

10.1073/pnas.092547099

10.1128/IAI.00541-09

10.1128/JB.00184-09

Thông tin
Thông tin xuất bản

Infection and Immunity

Tập 79 Số 9

3697-3710

Thông tin tác giả